Subgroup analyses indicated that patients with high tumor burden (MRD ≥ 10 -2 ) in the non-transplant group showed a trend toward reduced OS and LFS, though statistical significance was not reached, likely due to limited sample size ( Supplementary Figure S1 ).
← all excerpts
Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.
1
—
—